A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Trial Profile

A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Risankizumab (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Sep 2017 Planned primary completion date changed from 27 Jun 2018 to 14 Aug 2018.
    • 21 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 24 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top